OrbiMed’s PTC Therapeutics PTCT Stock Holding History

OrbiMed’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-50,000	Closed	-$2.41M	–	140
2015 Q2	$2.41M	Buy	+50,000	New	+$2.92M	0.02%	126

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

OrbiMed's PTCT Position: Q2 2026 in Review

OrbiMed held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 49,100 shares worth $4.01M. The position accounts for 0.07% of the portfolio, ranked #108.

OrbiMed first reported a position in PTCT in Q1 2014 and has held it in 13 quarters since. The position peaked at $94M in Q2 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

OrbiMed held 49,100 shares of PTC Therapeutics worth $4.01M as of Q2 2026.
OrbiMed left its PTC Therapeutics share count unchanged in Q2 2026.
PTC Therapeutics made up 0.07% of OrbiMed's portfolio in Q2 2026, its #108 holding.
OrbiMed first reported a position in PTC Therapeutics in Q1 2014 and has held it in 13 quarters since.
OrbiMed's PTC Therapeutics position peaked at $94M in Q2 2019.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.